ARS Pharmaceuticals Total Revenue

The latest total revenue for SPRY is $120M as of June 2026. That compares with $110M in the prior-year period — up 5.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside ARS Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPRY's total revenue moved from $110M to $120M — a 5.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ARS Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, SPRY currently prints $120M for total revenue, while the sector average sits near $110B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at ARS Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $120M for SPRY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting SPRY's total revenue ($120M), review year-over-year change from $110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.